00:00It's Benzinga, bringing Wall Street to Main Street.
00:02Pfizer reported first quarter earnings and revenue above estimates,
00:06and reaffirmed its 2026 outlook as growth in recently launched and acquired product-supported
00:11results, according to CNBC. Older top-selling drugs, including Eliquis, drove demand and
00:18offset declining revenue from Pfizer's COVID-19 vaccine and antiviral pill Paxlovid.
00:25Adjusted earnings per share came in at $0.75 versus $0.72 expected, while revenue reached
00:31$14.45 billion compared with $13.79 billion expected. The company reported revenue of $14.45
00:38billion for the first quarter, up 5% from the same period a year ago, as growth in key products
00:44offset weakness in its COVID business. Pfizer reaffirmed its 2026 outlook, expecting adjusted
00:51profit of $2.80 to $3 per share, and revenue of $59.5 billion to $62.5 billion, roughly flat
01:01or slightly below 2025 levels.
01:04For all things money, visit Benzinga.com.
Comments